How these medications are prescribed, dosed, and supported can dramatically impact your outcomes
Can they do this
Indeed, GLP-1RAs have evolved over time such that the frequency of dosing has decreased from twice-daily (exenatide, BD) [65], to once-daily (liraglutide, lixisenatide) [66, 67] to once-weekly (dulaglutide, exenatide QW, semaglutide) [5, 6], suggesting a higher adherence potential for the longer-acting agents (Table 2)
( [7] )) throughout the report
For example, only eight studies assessed treatment with the newer GLP-1 drugs, and the maximum follow-up period in these studies was 12 months after medication stopped